IDEAYA Biosciences

Company snapshot

IDEAYA is an oncology-focused precision medicine company. Our teams are committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. We are advancing therapeutics that have the potential to be first-in-class and/or best-in-class, with a primary focus in synthetic lethality – an emerging class of precision medicine targets. IDEAYA

• 14 active pipeline program(s) linked via ClinicalTrials.gov.
• 12 US patent(s) indexed to this assignee profile.
• 14 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for IDEAYA Biosciences. Not investment advice.

• Peer + 0 momentum

  Coherus Oncology

  TA overlap score 25

• Peer + 0 momentum

  Astellas Pharma

  TA overlap score 24.4

• Peer + 0 momentum

  TScan Therapeutics

  TA overlap score 21.8

• Peer + 0 momentum

  Pyxis Oncology

  TA overlap score 21.6

Recent activity

Latest pipeline, patent, and corporate events for IDEAYA Biosciences.

1. Jun 8, 2026 Clinical update

   IDE397-001 — Phase 1

2. Jun 8, 2026 Clinical update

   IDE196-009 — Phase 2

3. Jun 8, 2026 Clinical update

   IDE196-002 — Phase 3

4. Jun 8, 2026 Clinical update

   IDE196-002 — Phase 3

5. May 26, 2026 Clinical update

   IDE196 — Phase 3

View all clinical trial activity →

• What is IDEAYA Biosciences?

  IDEAYA Biosciences is a pharma organization headquartered in South San Francisco, USA. It trades on NYSE under ticker IDYA. Primary therapeutic focus areas include Uveal Melanoma, HLA-A2 negative metastatic uveal melanoma, Metastatic Uveal Melanoma, Advanced Solid Tumors, Neoplas

• Is IDEAYA Biosciences publicly traded?

  Yes. IDEAYA Biosciences is listed with ticker IDYA on NYSE per SEC EDGAR records linked on this profile.

• What drugs does IDEAYA Biosciences develop or market?

  We link 12 drug profile(s) where IDEAYA Biosciences is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/ideaya-biosciences#company-drugs.

• What are the latest developments for IDEAYA Biosciences?

  In the last 12 months our linked public records show 14 trial program update(s) and 1 US patent grant(s) tied to this profile.

• What therapeutic areas does IDEAYA Biosciences focus on?

  IDEAYA Biosciences focuses on Uveal Melanoma, HLA-A2 negative metastatic uveal melanoma, Metastatic Uveal Melanoma based on our analysis of their pipeline programs and drug development activities.